Liu, Y.; Wang, C.-L.; Pang, Z.-Q.; Gao, K.; Shen, L.-K.; Xu, W.-H.; Ren, M.-H.
Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12, 1861.
https://doi.org/10.3390/jcm12051861
AMA Style
Liu Y, Wang C-L, Pang Z-Q, Gao K, Shen L-K, Xu W-H, Ren M-H.
Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. Journal of Clinical Medicine. 2023; 12(5):1861.
https://doi.org/10.3390/jcm12051861
Chicago/Turabian Style
Liu, Yang, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, and Ming-Hua Ren.
2023. "Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer" Journal of Clinical Medicine 12, no. 5: 1861.
https://doi.org/10.3390/jcm12051861
APA Style
Liu, Y., Wang, C.-L., Pang, Z.-Q., Gao, K., Shen, L.-K., Xu, W.-H., & Ren, M.-H.
(2023). Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. Journal of Clinical Medicine, 12(5), 1861.
https://doi.org/10.3390/jcm12051861